August 6, 2007
Novartis AG announced on July 23 through Novartis Pharma and Ono Pharmaceutical that Exelon (rivastigmine), the only transdermal Alzheimer's disease medication, has been recommended for approval in the EU. In Japan, Novartis Pharma and Ono are jointly conducting a PIII...read more